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Abstract
Necroptosis is a newly identified type of programmed necrosis initiated by activation of tumor
necrosis factor alpha (TNF) and Fas. Necrostatin-1 is a specific inhibitor of necroptosis that reduces
ischemic tissue damage in experimental stroke models. We previously reported decreased tissue
damage and improved functional outcome after controlled cortical impact (CCI) in mice deficient in
TNF and Fas. Hence, we hypothesized that necrostatin-1 would reduce histopathology and improve
functional outcome after CCI in mice. Compared to vehicle- or inactive analogue-treated controls,
mice administered necrostatin-1 intracerebroventricularly prior to CCI had decreased cells with
plasmalemma permeability in injured cortex and dentate gyrus at 6 h (p < 0.05), decreased brain
tissue damage at 2 and 5 weeks after CCI (p < 0.05), improved motor performance (d 1–7, p < 0.05)
and improved performance in a Morris water maze paradigm (d 8–14, p < 0.01) after CCI. Improved
spatial memory was observed even when drug was administered 15 min after CCI (p < 0.05 for probe
trials). Necrostatin-1 treatment did not reduce caspase-3-positive cells in dentate gyrus or cortex,
consistent with a known caspase-independent mechanism of necrostatin-1. However, necrostatin-1
reduced brain neutrophil influx and microglial activation at 48 h (p < 0.05), suggesting a novel anti-
inflammatory effect in traumatic brain injury (TBI). The data suggest that necroptosis plays a
significant role in the pathogenesis of cell death and functional outcome after TBI, and that
necrostatin-1 may have therapeutic potential for patients with TBI and perhaps other forms of acute
brain injury.
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Introduction
Necroptosis is a recently discovered, regulated form of programmed necrosis initiated by
activation of tumor necrosis factor alpha (TNF) and/or Fas that is distinct from caspase-
dependent apoptotic cell death (Degterev et al., 2005). In susceptible cell types such as Jurkat
cells and U937 monocytes, TNF or Fas induced cell death occurs by caspase-mediated
apoptosis. However, in the presence of caspase inhibitors, these cell types die in response to
TNF or Fas activation with ultrastructural features of necrosis (Denecker et al. 2001a; Denecker
et al. 2001b; Holler et al. 2000; Matsumura et al. 2000; Vanden Berghe et al. 2004a; Vanden
Berghe et al. 2002; Vanden Berghe et al. 2004b; Vercammen et al. 1998a; Vercammen et al.
1998b; Vercammen et al. 1997). This alternative, death receptor-mediated, necrosis-like mode
of cell death has been termed necroptosis (Degterev et al. 2005).
Using an in vitro cell death assay of U937 cells exposed to TNF and ZVAD to induce
necroptosis, a library screen of chemical compounds yielded a novel class of small molecule
necroptosis inhibitors known as necrostatins (Degterev et al. 2005). Necrostatin-1 is a specific
and potent inhibitor of necroptosis; it does not protect against caspase-dependent apoptosis, or
against nonspecific oxidative stress-induced necrosis (Degterev et al. 2005). Recently,
necrostatin-1 was shown to dose-dependently reduce infarction size with a wide therapeutic
window in a mouse middle cerebral artery occlusion (MCAO) stroke model, suggesting that
necroptosis may be an important mode of ischemic cell death in vivo (Degterev et al. 2005).
Here, we tested the hypothesis that necroptosis contributes to cell death after TBI, and that
treatment with necrostatin-1 would reduce histopathology and functional deficits after
controlled cortical impact (CCI) in mice. We found that necrostatin-1 reduced acute cellular
plasmalemma permeability, short- and long-term tissue damage, and motor and cognitive
deficits in mice subjected to CCI. The data suggest an important role for necroptosis in the
pathogenesis of TBI, and suggest that necrostatin-1 may be a novel therapeutic agent for the
treatment of patients with head injury and perhaps other acute central nervous system disorders
that feature necroptosis as a mode of cell death.
Materials and Methods
For all studies, investigators were masked to treatment during surgery, data acquisition, and
analysis.
Controlled cortical impact
The controlled cortical impact (CCI) model was used as previously described with minor
modifications (Bermpohl et al. 2007). The trauma protocol was approved by the Massachusetts
General Hospital Institutional Animal Care and Use Committee and complied with the NIH
Guide for the Care and Use of Laboratory Animals. Mice (6–12 weeks of age) were
anesthetized with 4% isoflurane (Anaquest, Memphis, TN) in 70% N2O and 30% O2 using a
Fluotec 3 vaporizer (Colonial Medical, Amherst, NH) and positioned in a stereotaxic frame.
Anesthesia was maintained using 2–3% isoflurane. A 5 mm craniotomy was made using a
portable drill and trephine over the left parieto-temporal cortex, and the bone flap was removed.
Mice were then subjected to CCI using a pneumatic cylinder with a 3-mm flat-tip impounder,
velocity 6 m/s, set depth of 0.6 (for immunohistochemical studies requiring preserved cortical
tissue) or 1.0 mm (for histopathological and behavioral studies), and 100 ms impact duration.
The scalp was sutured closed and mice returned to their cages to recover from anesthesia.
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Administration of necrostatins and related compounds
Necrostatin-1 (5-[(7-chloro-1H-indol-3-yl)methyl]-3-methyl-2,4-imidazolidinedi-one) (Teng
et al. 2005), vehicle, or an inactive analogue of necrostatin-1 (5-[(7-chloro-1H-indol-3-yl)
methyl]-1,3-dimethyl-2,4-imidazolidinedione (6 ul each) was administered into the left
cerebral ventricle (co-ordinates relative to bregma: 0.1mm posterior, 1 mm lateral, 2 mm deep)
before or at various times after CCI. For all experiments, a 4 mM solution of necrostatin-1 in
methyl-beta-cyclodextrin (Sigma, St. Louis, MO) was used.
Assessment of lesion Volume
Morphometric image analysis (MCID, Imaging Research Inc, St. Catherines, Ontario, Canada)
was used to determine lesion volume and brain tissue loss after CCI. Mice were deeply
anesthetized with isoflurane, decapitated, and brains were removed and frozen in nitrogen
vapor. Coronal brain sections (12 µm) were cut on a cryostat at 0.5 mm intervals from anterior
to the posterior and mounted on poly-L-lysine-coated slides. Sections were stained with
hematoxylin and the area of the lesion was quantitated using image analysis (Bermpohl et al.
2007). Lesion volume was expressed in mm3.
Evaluation of motor and Morris water maze performance
Vestibulomotor function was assessed using a wire-grip test (Hall 1989). Mice were placed on
a metal wire (45 cm long) suspended 45 cm above a foam pad and were allowed to traverse
the wire for 60 s. The latency that a mouse remained on the wire within a 60 s interval was
measured, and wire grip scores were quantitated using a 5-point scale (Bermpohl et al. 2006).
A score of one point was given if the mouse failed to hold on to the wire with both sets of fore
paws and hind paws together; two points were given if the mice held on to the wire with both
forepaws and hind paws but not the tail; three points were given if the mouse used its tail along
with both forepaws and both hindpaws; four points were given if the mouse moved along the
wire on all four paws plus tail; and five points were given if mice that scored four points also
ambulated down one of the posts used to support the wire. Mice that were unable to remain on
the wire for less than 30 s were given a score of zero. The wire grip test was performed in
triplicate and an average value calculated for each mouse on each day of testing.
The Morris water maze (MWM) task was used to evaluate spatial memory performance as
previously described with minor modifications (Bermpohl et al. 2007). The apparatus consisted
of a white pool (83 cm diameter, 60 cm deep) filled with water to 29 cm depth with several
highly visible cues located on the walls of each of the four quadrants. Water temperature was
maintained 21–25°C. A clear plexiglass goal platform 10 cm in diameter was positioned 0.5
cm below the water’s surface approximately 15 cm from the southwest wall. Each mouse was
subjected to 1 or 2 trials per day. For each trial, mice were randomized to one of four starting
locations (north, south, east, or west) and placed in the pool facing the wall. Mice were given
a maximum of 60 s to find the submerged platform. If the mouse failed to reach the platform
by 60 s, it was placed on the platform by the experimenter and allowed to remain there for 10
seconds. Mice were placed in a warming chamber for at least 4 minutes between trials. The
average latency to the goal platform from the four starting locations was recorded as the latency
for that trial. To control for possible differences in visual acuity or sensorimotor function
between groups, two subsequent trials were performed using a visible platform raised 0.5 cm
above the surface of the water. Following the visible platform trials, a probe trial was performed
on the following day in which the mouse was given 60 s to swim in the tank with the goal
platform removed. The time spent in the target quadrant (probe time) was recorded for each
mouse. Performance in the MWM was quantitated by latency to the platform.
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Administration of propidium iodide and detection of PI-positive cells
Propidium iodide (PI; 10mg/ml, Sigma, St. Louis, MO) was diluted in 0.9% NaCl and 1 mg/
kg was administered 1 h prior to sacrifice by intraperitoneal injection in a total volume of not
more than 100 ul. Mice were killed at 6 h after CCI, the brains frozen in nitrogen vapor, and
cryostat brain sections (12 um) were cut at 150–200 um intervals from anterior to posterior
hippocampus. Cryostat sections were placed on poly-L-lysine slides and stored at −80°C. For
detection of PI-labeled cells, brain sections were fixed in 100% ethanol for 10 min at room
temperature, coverslipped with Permount (Biomeda, Foster City, CA) and photographed on a
Nikon Eclipse T300 fluorescence microscope (Tokyo, Japan) using excitation/emission filters
568/585 for PI.
Caspase-3, neutrophil and astrocyte immunohistochemistry
At 48 h after CCI, mice were anaesthetized with isoflurane and the brain rapidly removed intact
and frozen at −80°C. Coronal brain sections (12 µm) were placed on poly-L-lysine coated
slides and were fixed in 100% ethanol at room temperature for 10 min. Slides were washed in
phosphate buffered saline (pH 7.4; PBS). Sections were blocked for 30 min in PBS with 3%
normal goat serum and then incubated over night at 4°C with rabbit polyclonal anti-caspase-3
antibody (1:1000, CM1, Idun Pharmaceuticals, La Jolla, CA). The CM-1 antibody reacts
specifically with the p18 fragment of cleaved caspase-3 but not with full-length caspase-3
(Srinivasan et al. 1998). Sections were then washed in PBS and incubated with goat anti-rabbit
IgG-Cy-3 conjugate (1:300, Jackson ImmunoResearch, West Grove, PA) for 60 min. To detect
neutrophils and astrocytes, frozen brain sections were air-dried and fixed in 100% ethanol at
room temperature for 10 min. Slides were washed in PBS (pH 7.4) and blocked for 30 min in
PBS with 3% normal goat serum, then incubated overnight at 4°C with PE-conjugated rat anti-
mouse neutrophil antibody M1/70 (1:200; BD-Biosciences, Franklin Lakes, NJ) or with Cy3-
conjugated monoclonal anti-glial fibrillary acidic protein (GFAP) antibody (1:2,000; Sigma,
St. Louis, MO). Sections were washed in PBS, rinsed with water, air-dried and cover-slipped
with Crystal mount (Biomeda, Foster city, CA). Sections were analyzed on a Nikon Eclipse
T300 fluorescence microscope. Excitation/emission filters were 568/585 for both M1/70-PE
and Cy3.
Assessment of PI-positive, neutrophil and caspase-3-positive cell counts
Cell counts were determined as previously described (Bermpohl et al. 2007). The regions of
interest in injured cortex (200× microscopic fields, 1100 × 1100 um) for PI-and caspase-3-
positive cell counts were a cortical field at the medial edge and a cortical field at the lateral
edge of the contusion. Three coronal brain sections separated by at least 150 um were randomly
sampled from brain regions between bregma −1.90 to −2.70 for a total of six × 200 cortical
fields assessed per animal. For cell counts in dentate gyrus, two adjacent × 200 fields (1100 ×
1100 um) encompassing the upper and lower blades of the dentate gyrus were evaluated in the
three brain sections selected for cortical cell counts (above). Cell count data for each mouse
were reported as the average of the cortical or hippocampal fields.
For the estimation of neutrophils in injured cortex, cortical brain fields (× 200; 1100 ×1100
um) from three brain sections separated by at least 150 mm and within the approximate center
of the contusion were selected for analysis. Neutrophils were photographed and quantitated in
three × 200 cortical fields randomly chosen from each brain section. Thus, a total of nine ×
200 fields were analyzed per mouse. From these data, an average neutrophil count per × 200
field was obtained for each animal.
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Microglia immunohistochemistry
At 48 h after CCI mice were anesthetized with isoflurane and transcardially perfused with 4%
paraformaldehyde. The brain was removed and frozen in nitrogen vapor, and stored at −80°C.
Coronal brain sections (12 µm) were placed on poly-L-lysine-coated slides and stored at −80°
C. Brain sections were washed with PBS, rinsed with water, air-dried and cover-slipped with
crystal/mount (Biomeda, Foster city, CA, USA), and analyzed on a Nikon Eclipse T300
fluorescence microscope. Excitation/emission filters were 568/585 for both M1/70-PE and
Cy-3.
Microglia staining was performed using paraformaldehyde-fixed brain tissue. Cryostat-fixed
brain sections were treated with 1% hydrogen peroxide in PBS. The slides were blocked in
PBS with 3% normal goat serum for 1 h and incubated overnight at 4°C with rabbit anti-Iba-1
antibody (1:200; Wako Pure Chemical Industries Ltd., Osaka, Japan). The sections were then
washed in PBS with 1% normal goat serum and incubated with biotinylated goat anti-rabbit
immunoglobulin G (1:200; Vector Laboratories, Burlingame, CA, USA) antibody for 1 h. After
washing, the signal was detected using an ABC kit (Vector Labs) and diaminobenzidine
(Vector Labs).
Quantitation of astrocytes and activated microglia in mouse cortex after CCI
For the analysis of GFAP-positive astrocytes or Iba-1-positive microglia, photomicrographs
of × 200 fields from the medial and lateral edges of the contusion were analyzed from three
brain sections as described above (cell counts). Using MCID image analysis software, activated
GFAP-positive astrocytes or IBA-1-positive microglia were quantified as previously described
(Bermpohl et al. 2007).
Statistical analyses
Data are mean ± SEM. Cell count data were analyzed by rank sum test. Lesion volume and
brain tissue loss data, and probe trial data were analysed by ANOVA on ranks and rank sum
tests. Motor and Morris water maze test data (hidden and visible platform acquisition latencies)
were analyzed by two factor repeated measures ANOVA (group × time). For all comparisons,
p < 0.05 was regarded as significant.
Results
All animals survived CCI and the experimental period. No overt toxic effects of necrostatin-1,
inactive analogue, or vehicle treatment were observed in any of the mice studied.
Necrostatin-1 inhibits brain tissue damage after CCI
We first examined the effect of necrostatin-1 treatment on brain lesion size after CCI. In animals
administered necrostatin-1 immediately prior to CCI (pretreated), lesion size was significantly
reduced by approximately 30–40% compared to pretreatment with vehicle or inactive analogue
(Figure 1A). Pretreatment with necrostatin-1 also reduced lesion size assessed at 35 days after
CCI (Figure 1A), suggesting that protection against brain tissue damage is a persistent effect
of necrostatin-1 in our CCI model. To determine the therapeutic window for necrostatin-1,
drug or vehicle was administered to mice before or at various times after CCI and lesion size
assessed at two weeks. Figure 1B shows that administration of necrostatin-1 pre-injury or at
15 but not 30 min after CCI significantly reduced brain lesion size.
Necrostatin-1 improves recovery of motor performance after CCI
We next determined the effect of necrostatin-1 treatment on postinjury motor function. No
difference in baseline motor function before CCI was observed between groups of mice
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administered drug, vehicle, or inactive analogue (Figure 2). Following CCI, recovery of motor
function was significantly improved in necrostatin-1-treated mice versus mice treated with
inactive analogue or vehicle (Figure 2A, p < 0.05 for group effects). In contrast, mice
administered necrostatin-1 at 5 min postinjury had wire grip performance similar to vehicle-
treated mice, suggesting a short therapeutic window for necrostatin-1 with respect to motor
dysfunction (Figure 2B).
Necrosatin-1 improves spatial memory acquisition after CCI
To examine the effect of necrostatin-1 on postinjury cognitive function, we assessed
performance of injured mice pretreated with necrostatin-1, inactive analogue, or vehicle in a
Morris water maze paradigm. Mice administered necrostatin-1 prior to CCI had significantly
improved latency to the hidden platform compared to vehicle- or inactive analogue-treated
mice, whereas all three groups had similar performance in visible platform tests (Figure 3A).
The protective effect of necrostatin-1 in injured mice could not be attributed to effects on
baseline MWM performance as naïve (uninjured) mice administered necrostatin-1 or vehicle
did not differ in acquisition of hidden or visible platform tests (Figure 3B). Results of probe
trial testing are shown in Figure 3C. Injured mice pretreated with necrostatin-1 performed
similarly to sham-injured mice (administered vehicle or necrostatin-1) and significantly better
compared to injured vehicle- or inactive analogue-treated mice. No difference in probe trials
was observed between sham-injured vehicle- or drug-treated mice. In a separate set of
experiments, mice were treated with necrostatin-1 or vehicle at various times after CCI and
MWM performance was assessed as above. Although no significant differences between
groups were observed in hidden platform trials with limited numbers of mice per group (data
not shown), mice given necrostatin-1 at 5 or 15 minutes postinjury had significantly improved
probe trial performance vs. vehicle treated animals (p < 0.05, Figure 3C).
Necrostatin-1 reduces acute plasmalemma permeability in injured cells after CCI
Plasmalemma permeability is a hallmark of necrotic, including necroptotic, cell death. To begin
to address cellular mechanisms of reduced postinjury tissue damage, we assessed the effect of
necrostatin-1 treatment on loss of plasmalemma integrity in cortical and hippocampal brain
regions using in vivo propidium iodide labeling. Compared to vehicle treated mice, mice
administered necrostatin-1 prior to CCI had decreased numbers of PI-positive cortical cells at
6 h after CCI in injured cortex and dentate gyrus brain regions (p < 0.05, Figure 4A, B),
suggesting reduction of necrosis-like cellular injury. Because plasmalemma permeability may
also be associated with late apoptotic mechanisms, we next assessed the effect of necrostatin-1
on caspase-3 activation in the same brain regions used to assess plasmalemma integrity, at 48
h after CCI. Figure 5A shows representative immunohistochemical detection of activated
caspase-3 in injured cortex and dentate gyrus. No difference in numbers of cells with activated
caspase-3 were observed between necrostatin-1 and vehicle-treated mice (Figure 5B).
Necrostatin-1 inhibits cellular neuroinflammation after CCI
To assess the potential effect of necrostatin-1 on neuroinflammation after CCI, we examined
brain neutrophil counts, astrocytosis, and the microglial response to CCI in injured mouse
cortex at 48 h in mice pretreated with necrostatin-1 or vehicle. This time point was chosen
because all three of these inflammatory markers are robust in injured brain at 48 h (Bermpohl
et al. 2007). Figure 6A shows that brain neutrophil counts in injured cortical brain regions were
decreased by approximately 50% in necrostatin-1-treated mice. Similarly, necrostatin-1
markedly inhibited the staining intensity of activated microglia detectable with Iba-1 antibody
(Figure 6B). In contrast, immunohistochemical density analysis of astrocytes showed no
differences between groups (data not shown).
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Discussion
We provide strong evidence that necroptosis is an important mechanism of cell death and
neurological dysfunction after TBI. Necrostatin-1, a specific inhibitor of necroptosis (Degterev
et al. 2005), reduced acute cellular injury, brain tissue damage, motor dysfunction, and spatial
learning deficits after CCI in mice. Indeed, necrostatin treatment recapitulated all of the
protective effects of TNF/Fas knockout in our CCI model, consistent with the known
mechanism of action of necrostatins in cultured cells (Degterev et al. 2005). Importantly,
clinically relevant effects of necrostatin-1 on learning and memory deficits were observed even
when necrostatin-1 was administered 15 minutes after CCI. Necrostatin-1 treatment also
markedly suppressed the neutrophil and microglial responses to CCI, suggesting a heretofore-
unreported anti-inflammatory effect in acute brain injury. The data suggest a fundamental role
for necroptosis in the pathogenesis of TBI.
Two lines of evidence suggest that necrostatin-1 specifically inhibits necroptosis in our CCI
model. First, pretreatment with necrostatin-1 reduced the numbers of cells with loss of
plasmalemma integrity, a hallmark of necroptosis, in cortex and dentate gyrus 6 h after CCI.
Second, necrostatin-1 did not reduce the number of caspase-3 positive cells in cortex or dentate
gyrus at 48 h after CCI, a time of maximal cleaved caspase-3 expression in our CCI model.
These findings are consistent with in vitro data showing a specific effect of necrostatin-1 on
programmed necrosis (Degterev et al. 2005), and suggest that necroptotic cell death may be a
primary mode of death for a subpopulation of neurons and perhaps other cell types injured
early after CCI.
Based on prior studies showing a beneficial effect of necrostatin-1 in ischemic brain injury and
our previous report of reduced tissue damage in mice lacking functional TNF and Fas
(Bermpohl et al. 2007), we anticipated that necrostatin-1 would reduce posttraumatic lesion
size after CCI. Pretreatment with necrostatin-1 significantly reduced cavitary lesion size with
a magnitude similar to that obtained in rodents using cysteine protease inhibitors or apoptosis
gene knockout mice (Clark et al. 2000; Clark et al. 2006; Bermpohl et al. 2006, Bermpohl et
al. 2007). Moreover, necrostatin-1 treatment conferred long lasting reduction in postinjury
brain tissue damage after CCI, an effect not seen with strategies targeting caspases or Bid
(Bermpohl et al. 2006; Clark et al. 2006). These data suggest that necroptotic mechanisms
contribute to short- and long-term brain tissue loss after CCI.
The therapeutic window for necrostatin-1 to reduce lesion size was 15–30 minutes under the
conditions of our ICV administration protocol. In contrast, ICV administration of necrostatin-1
significantly reduced ischemic infarct size even when given as late as 6 h after experimental
middle cerebral artery occlusion and reperfusion (MCAO) in mice (Degterev et al. 2005). The
different therapeutic window for necrostatin-1 in MCAO versus CCI may reflect different
kinetics of necroptosis in the two brain injury models. In support of this possibility, we have
found that the onset of loss of cellular plasmalemma integrity, a hallmark of necroptosis, peaks
at 60 minutes after CCI in injured cortex and hippocampus (M Whalen, manuscript submitted).
Early loss of plasmalemma integrity was also reported in another (closed head injury) TBI
model (Farkas et al. 2006). In contrast, significant plasmalemma damage was not detected until
6 h after reperfusion in mice subjected to MCAO (Unal Cevik and Dalkara 2003; Unal-Cevik
et al. 2004). The short therapeutic window for necrostatin-1 suggests that necroptosis is rapidly
initiated after CCI, and implicate necroptotic mechanisms as one possible cause of traumatic
membrane poration in the CCI model (Farkas et al. 2006; Kristensen et al. 2003; Lee et al.
1999). In support of this notion, induction of TNF and Fas receptor and assembly of TNFR1
and Fas DISC are rapid events measured in minutes to hours after experimental TBI (Beer et
al. 2000; Lotocki et al. 2004; Qiu et al. 2002).
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We found significant improvement in posttraumatic motor dysfunction in mice pre-treated with
necrostatin-1. Necrostatin-1 also reduced sensorimotor deficits after MCAO in mice, albeit
with a much longer therapeutic window compared to CCI (Degterev et al. 2005). In the current
study, necrostatin-1 administration at 5 minutes after CCI was not effective in reducing
postinjury motor deficits. Thus, necroptotic pathways that influence posttraumatic motor
deficits may have a shorter therapeutic window for necrostatin-1 treatment compared with
mechanisms responsible for cell death and cognitive outcome in the CCI model.
Perhaps the most clinically relevant finding in our study was that necrostatin-1 treatment
partially reduced cognitive deficits induced by CCI. Compared to vehicle or inactive analog,
necrostatin-1 led to significant improvement in injured mice in hidden platform and probe trials
(the latter being a sensitive and specific test of spatial learning). The finding that necrostatin-1-
treated and control groups performed equally well on visible platform trials suggests that
improved MWM performance was not attributable to differences in motivation, swim speed,
sensorimotor function, or other non-spatial brain functions, but likely represents improved
spatial memory acquisition and retention. Necrostatin-1 improved probe trial performance in
injured mice even when administered at 15 min after CCI, suggesting that necrostatin-1 might
be useful for treatment of postinjury cognitive deficits in humans with TBI. Even with a narrow
therapeutic window, rapid postinjury administration of necrostatins using an intravenous
protocol would be feasible in patients with witnessed TBI, such as soldiers on the battlefield.
Additionally, the therapeutic window for necrostatins might be longer in humans compared to
mice. Studies examining the efficacy of intravenous necrostatin dosing paradigms on post-CCI
cognitive deficits are currently underway in our laboratory.
Pretreatment with necrostatin-1 markedly reduced brain neutrophil influx and microglial
activation at 48 h after CCI. Little is known regarding the molecular pathways that activate
microglia after TBI, however a previous study showed that small molecule inhibitors of
microglial activation can reduce spatial learning deficits associated with neurodegenerative
disease in mice (Ralay Ranaivo et al. 2006). This report notwithstanding, reduced inflammation
is not a prerequisite for improved MWM performance mediated by TNF/Fas signaling
pathways (Bermpohl et al. 2007). Our data suggest that necroptotic signaling pathways
contribute to cellular inflammation in injured brain, and raise the possibility that necrostatin-1
may inhibit pro-inflammatory gene expression after TBI. This hypothesis is currently under
investigation in our laboratory.
The present study adds necroptosis to the list of cell death mechanisms that operate in brain
after TBI. Other TBI-related cell death mechanisms include caspase-mediated apoptosis and
caspase-independent programmed cell death (apoptosis inducing factor), as well as oxidative
stress (Aoyama et al. 2002; Zhang et al. 2002; Zhang et al. 2005). Programmed necrosis
(necroptosis) is also relevant to TBI, although further proof of this concept awaits development
of specific reagents to the molecular target(s) of necrostatin-1. Further work is needed to
identify necroptosis signaling pathways after TBI, and to identify the molecular target(s) that
mediate protection by necrostatin-1. In addition, other necrostatins with increased activity and
serum half-life should be tested in brain injury models (Jagtap et al. 2007; Wang et al. 2007).
We conclude that necroptosis, a novel form of programmed necrosis triggered by death
receptors, plays a significant role in cell death and neurological dysfunction after CCI in mice.
The current study provides proof of principle that necrostatin-1 and perhaps other necrostatins
are promising therapeutic agents to reduce the histopathological and functional neurological
sequelae of TBI.
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Figure 1.
Brain lesion volume is reduced in Necrostatin-1 treated mice after controlled cortical impact
(CCI). (A) Pretreatment with necrostatin-1 reduced lesion volume at 14 days after CCI
compared to treatment with vehicle (Veh) or inactive analogue (ANA)(p < 0.001 ANOVA, *p
< 0.05 versus ANA or Veh). Pretreatment with necrostatin-1 also reduced lesion size assessed
at 35 days (*p < 0.05). For 14 days, n = 7–16/group; for 35 days, n = 4/group). (B) Necrostatin-1
was administered after CCI at the times indicated. Post injury treatment with necrostatin-1
reduced lesion size compared to vehicle when administered at 5 or 15 min but not 30 min after
CCI (*p < 0.05, n = 4–5/group).
You et al. Page 11
J Cereb Blood Flow Metab. Author manuscript; available in PMC 2010 March 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Reduced motor deficits after controlled cortical impact (CCI) in Necrostatin-1 treated mice.
Vestibulo-motor function assessed by the wire grip test was similar among all groups prior to
CCI. Post injury motor function was significantly improved in mice administered necrostatin-1
(Nec-1) compared to inactive analogue (ANA) or vehicle (Veh) (p < 0.05 for group effect,
n=8/group). (B) Administration of necrostatin-1 (n = 5) to mice 5 min after CCI did not affect
motor performance vs. vehicle treated animals (n = 9).
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Figure 3.
Necrostatin-1 treatment improves Morris water maze (MWM) performance after controlled
cortical impact (CCI). (A) Morris water maze performance in naive adult animals administered
necrostatin-1 (Nec-1) or vehicle (Veh). No difference in performance was observed between
uninjured Veh- and Nec-1-treated mice in hidden or visible platform trials, or in probe trials
(n=4/group). (B) Performance in the hidden platform trials was significantly improved in
animals pretreated with Necrostatin-1 versus inactive analogue (ANA) or vehicle (Veh) (p <
0.05 for group effect, n = 7/group). (C) Probe trial performance in mice administered
Necrostatin-1 (Nec-1) vs. Veh or ANA. No effect of drug treatment was observed in sham
injured mice on probe trial performance, however injured mice administered Nec-1 before or
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at 5 or 15 minutes after CCI had improved performance vs. vehicle-treated animals (*p < 0.05),
n= 4–9/group).
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Figure 4.
Pre-treatment with necrostatin-1 (Nec-1) reduces propidium iodide (PI)-positive cells at 6 h
after controlled cortical impact (CCI) in injured cortex and hippocampus. (A) Representative
photomicrographs showing reduced numbers of PI-positive cells in cortical and dentate gyrus
brain regions after CCI in Nec-1 and vehicle-treated mice. Magnification × 200. (B)
Quantitation of PI-positive cells in injured cortex and dentate gyrus. *p < 0.01 vs. vehicle
treated animals (n = 12/group).
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Figure 5.
No effect of necrostatin-1 on caspase-3-positive cells after controlled cortical impact.
Necrostatin-1 or vehicle was administered to mice (n = 7–9/group) immediately before CCI
and caspase-3 positive cells were quantitated in injured cortex and dentate gyrus at 48 h. (A)
Representative photomicrographs showing similar numbers of caspase-3-positive cells in
dentate gyrus after CCI in Necrostatin-1 (Nec-1) and vehicle-treated (Veh) mice. (B)
Quantitation of caspase-3-positive cells in injured cortex and dentate gyrus.
You et al. Page 16
J Cereb Blood Flow Metab. Author manuscript; available in PMC 2010 March 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
Pre-treatment with necrostatin-1 reduces neuroinflammation assessed at 48 h after controlled
cortical impact. (A) Representative photomicrographs (top panels) showing neutrophil
accumulation in injured cortex in mice administered vehicle (Veh) or necrostatin-1 (Nec-1).
Bottom panels show quantitation of neutrophils in injured cortices of Veh and Nec-1 treated
mice. * p < 0.05 vs. Veh (n = 10–11/group). (B) Marked reduction in microglial activation in
mice administered necrostatin-1 vs. vehicle prior to controlled cortical impact. Upper panels
show representative immunohistochemical staining using the microglial specific marker
IBA-1. The graph in the lower panel shows quantitation of microglial activation using image
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analysis software. *p < 0.05 vs. vehicle (n = 7–9/group). Magnification × 200 in all
photomicrographs.
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